FLXNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions...

Stats
本日の出来高	0.00
平均出来高	2.17M
時価総額	0.00
EPS	$-0.600 ( 2021-11-12 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.321 (3.52%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-19	Newtyn Management, Llc	Sell	5 900 000	Common Stock, par value $0.001 per share
2021-11-18	Newtyn Management, Llc	Buy	0	Common Stock, par value $0.001 per share
2021-11-19	Stejbach Mark	Sell	12 631	Common Stock
2021-11-19	Stejbach Mark	Sell	25 000	Stock option (right to buy)
2021-11-19	Stejbach Mark	Sell	12 500	Stock option (right to buy)

INSIDER POWER
0.00
Last 99 transactions
Buy: 271 750 \| Sell: 9 779 666

ボリューム相関

長: 0.20 (neutral)

短: -0.90 (strong negative)

Signal:(61.022) Neutral

Flexion Therapeutics Inc 相関

10 最も正の相関
RETA	0.954
ZGNX	0.952
PLPC	0.948
FLMN	0.943
OSPN	0.943
FSLR	0.937
SFT	0.929
XLRN	0.925
ADMS	0.925
AAON	0.919

10 最も負の相関
EYE	-0.947
LMPX	-0.935
GBNH	-0.917
RYTM	-0.909
PSHG	-0.909
MDRX	-0.9
CSTE	-0.9
TCPC	-0.899
ALHC	-0.899
STIM	-0.896

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Flexion Therapeutics Inc 相関 - 通貨/商品

0.25
( neutral )

0.57
( weak )

0.53
( weak )

0.51
( weak )

0.43
( neutral )

-0.36
( neutral )

Flexion Therapeutics Inc 財務諸表

Annual	2020
収益:	$85.55M
総利益:	$66.30M (77.50 %)
EPS:	$-2.53

FY	2020
収益:	$85.55M
総利益:	$66.30M (77.50 %)
EPS:	$-2.53

FY	2019
収益:	$72.96M
総利益:	$63.00M (86.35 %)
EPS:	$-3.93

FY	2018
収益:	$22.52M
総利益:	$15.19M (67.43 %)
EPS:	$-4.49

Financial Reports:

No articles found.

Flexion Therapeutics Inc

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.